{"id":1672,"date":"2019-11-27T16:30:53","date_gmt":"2019-11-27T21:30:53","guid":{"rendered":"https:\/\/bridgebioprod.wpengine.com\/?p=1672"},"modified":"2022-06-23T11:34:12","modified_gmt":"2022-06-23T15:34:12","slug":"bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4","status":"publish","type":"post","link":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","title":{"rendered":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"\r\n<p>Palo Alto, CA, November 27, 2019 &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced grants of inducement awards to its Chief Operating Officer, Brian Stolz; its Chief Accounting Officer, Yi Ching Yau; and one additional employee, on November 13, 2019.<\/p>\r\n\r\n\r\n\r\n<p>The Company granted Mr. Stolz (i)\u00a0non-qualified stock options to purchase 102,081 shares of the Company\u2019s common stock with an exercise price of $26.28 per share, the closing price of BridgeBio\u2019s common stock as reported by Nasdaq on November 13, 2019, (ii)\u00a0a restricted stock award of 22,839 shares of the Company\u2019s common stock, (iii)\u00a0 a time-based restricted stock unit award of 106,469 units, each of which relates to one share of the Company\u2019s common stock and (iv)\u00a0a performance-based restricted stock unit award of 53,234 units, each of which relates to one share of the Company\u2019s common stock.\u00a0<\/p>\r\n\r\n\r\n\r\n<p>The Company granted Ms. Yau (i) non-qualified stock options to purchase 78,148 shares of the Company\u2019s common stock with an exercise price of $26.28 per share, the closing price of BridgeBio\u2019s common stock as reported by Nasdaq on November 13, 2019 and (ii)\u00a0a time-based restricted stock unit award of 20,376 units, each of which relates to one share of the Company\u2019s common stock.<\/p>\r\n\r\n\r\n\r\n<p>The Company granted one additional employee a time-based restricted stock unit award of 26,164 units, each of which relates to one share of the Company\u2019s common stock.<\/p>\r\n\r\n\r\n\r\n<p>The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have a 10-year term and vest over four years, with 25% vesting on the first anniversary of the individual\u2019s hire date and the remaining 75% vesting in substantially equal monthly installments over the next 36 months.\u00a0 The restricted stock award to Mr. Stolz was fully vested upon grant. The time-based restricted stock unit awards vest over four years, with 25% vesting on the first anniversary of the specified vesting commencement date and the remaining 75% vesting in substantially equal quarterly installments over the next 12 quarters.\u00a0 Mr. Stolz\u2019s performance-based restricted stock unit awards vest in a single installment on September 20, 2022 based on performance metrics.\u00a0 The vesting of the equity awards is subject to the grantee\u2019s continued service with BridgeBio through the applicable vesting dates and, in the case of Mr. Stolz\u2019s time-based awards, to acceleration upon the occurrence of certain events as set forth in the award agreement evidencing the awards.<\/p>\r\n\r\n\r\n\r\n<p>The above-described awards were granted outside of BridgeBio\u2019s stockholder-approved equity incentive plans pursuant to BridgeBio\u2019s 2019 Inducement Equity Plan (the \u201cPlan\u201d). The awards were approved by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the individuals entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).\u00a0 The Plan was adopted by BridgeBio\u2019s board of directors in November 2019.<\/p>\r\n\r\n\r\n\r\n<p><strong>About BridgeBio<\/strong><\/p>\r\n\r\n\r\n\r\n<p>BridgeBio is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio\u2019s pipeline of over 15 development programs includes product candidates ranging from early discovery to late-stage development.<\/p>\r\n\r\n\r\n\r\n<p><strong>Contact:<\/strong><br \/>BridgeBio Pharma, Inc. <br \/>Grace Rauh <br \/><a href=\"mailto:Grace.rauh@bridgebiodev.wpengine.com\">Grace.rauh@bridgebiodev.wpengine.com<\/a><br \/>(917) 232-5478<\/p>\r\n\r\n\r\n\r\n<p>Source: BridgeBio Pharma, Inc.<\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>Palo Alto, CA, November 27, 2019 &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced grants of inducement awards to its Chief Operating Officer, Brian Stolz; its Chief Accounting Officer, Yi Ching Yau; and one additional employee, on November 13, 2019. The Company granted Mr. Stolz (i)\u00a0non-qualified stock [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[10],"tags":[],"class_list":["post-1672","post","type-post","status-publish","format-standard","hentry","category-press-release"],"acf":{"external_link":"","meta_short_title":"BridgeBio Reports Inducement Grants under Nasdaq Rule","meta_description":"","meta_share_image":false,"people":false,"presentation":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Inducement Grants | 11\/27\/19 | BridgeBio<\/title>\n<meta name=\"description\" content=\"BridgeBio announced grants of inducement awards to its COO, Brian Stolz; its Chief Accounting Officer, Yi Ching Yau; &amp; one other employee.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inducement Grants | 11\/27\/19 | BridgeBio\" \/>\n<meta property=\"og:description\" content=\"BridgeBio announced grants of inducement awards to its COO, Brian Stolz; its Chief Accounting Officer, Yi Ching Yau; &amp; one other employee.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/\" \/>\n<meta property=\"og:site_name\" content=\"BridgeBio\" \/>\n<meta property=\"article:published_time\" content=\"2019-11-27T21:30:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-23T15:34:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Brandon Keller\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:site\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Brandon Keller\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/\",\"url\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/\",\"name\":\"Inducement Grants | 11\/27\/19 | BridgeBio\",\"isPartOf\":{\"@id\":\"https:\/\/bridgebio.com\/#website\"},\"datePublished\":\"2019-11-27T21:30:53+00:00\",\"dateModified\":\"2022-06-23T15:34:12+00:00\",\"author\":{\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/6cd954001e2cec42c2e8290f7c570325\"},\"description\":\"BridgeBio announced grants of inducement awards to its COO, Brian Stolz; its Chief Accounting Officer, Yi Ching Yau; & one other employee.\",\"breadcrumb\":{\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bridgebio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bridgebio.com\/#website\",\"url\":\"https:\/\/bridgebio.com\/\",\"name\":\"BridgeBio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bridgebio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/6cd954001e2cec42c2e8290f7c570325\",\"name\":\"Brandon Keller\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3f5f406075c438807a4d70dccadd771a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3f5f406075c438807a4d70dccadd771a?s=96&d=mm&r=g\",\"caption\":\"Brandon Keller\"},\"url\":\"https:\/\/bridgebio.com\/author\/bkeller\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inducement Grants | 11\/27\/19 | BridgeBio","description":"BridgeBio announced grants of inducement awards to its COO, Brian Stolz; its Chief Accounting Officer, Yi Ching Yau; & one other employee.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","og_locale":"en_US","og_type":"article","og_title":"Inducement Grants | 11\/27\/19 | BridgeBio","og_description":"BridgeBio announced grants of inducement awards to its COO, Brian Stolz; its Chief Accounting Officer, Yi Ching Yau; & one other employee.","og_url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","og_site_name":"BridgeBio","article_published_time":"2019-11-27T21:30:53+00:00","article_modified_time":"2022-06-23T15:34:12+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png","type":"image\/png"}],"author":"Brandon Keller","twitter_card":"summary_large_image","twitter_creator":"@BridgeBioPharma","twitter_site":"@BridgeBioPharma","twitter_misc":{"Written by":"Brandon Keller","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/","name":"Inducement Grants | 11\/27\/19 | BridgeBio","isPartOf":{"@id":"https:\/\/bridgebio.com\/#website"},"datePublished":"2019-11-27T21:30:53+00:00","dateModified":"2022-06-23T15:34:12+00:00","author":{"@id":"https:\/\/bridgebio.com\/#\/schema\/person\/6cd954001e2cec42c2e8290f7c570325"},"description":"BridgeBio announced grants of inducement awards to its COO, Brian Stolz; its Chief Accounting Officer, Yi Ching Yau; & one other employee.","breadcrumb":{"@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bridgebio.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/bridgebio.com\/#website","url":"https:\/\/bridgebio.com\/","name":"BridgeBio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bridgebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/6cd954001e2cec42c2e8290f7c570325","name":"Brandon Keller","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3f5f406075c438807a4d70dccadd771a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3f5f406075c438807a4d70dccadd771a?s=96&d=mm&r=g","caption":"Brandon Keller"},"url":"https:\/\/bridgebio.com\/author\/bkeller\/"}]}},"_links":{"self":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/1672"}],"collection":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/comments?post=1672"}],"version-history":[{"count":0,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/1672\/revisions"}],"wp:attachment":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/media?parent=1672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/categories?post=1672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/tags?post=1672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}